Abstract: Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists. The methods may comprise administering RARA agonists to patient populations.

Abstract: The present disclosure features, inter alia, methods of treating a patient who has been diagnosed with acute myelomonocytic leukemia (the M4 subtype of AML), acute monocytic leukemia (the M5 subtype of AML), or myelodysplastic syndrome (MDS). The methods include administering to the patient a therapeutically effective amount of a retinoic acid receptor-alpha (RARA) agonist or a pharmaceutically acceptable salt thereof. In one or more embodiments (e.g., in treating MDS), administering the RARA agonist or the pharmaceutically acceptable salt thereof commences prior to determining whether the patient expresses a RARA biomarker and/or without consideration of the status of the RARA biomarker.

Abstract: Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists. The methods may comprise administering RARA agonists to patient populations.